• English
  • Español
On April 25th, 2023, from 10:00 am to 4:00 pm ET, FDA is conducting a virtual (online only) public meeting on Patient-Focused Drug Development for Long COVID. The public meeting is intended to allow FDA to obtain patient perspectives on the impact of Long COVID or Post Acute Sequalae of SARS-CoV-2 (PASC).

FDA is interested in hearing patient perspectives on the following topics:

(1) health effects and daily impacts;
(2) current approaches to treatment;
(3) clinical trial participation.

For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patients and patient representatives in the audience.  

If you are a patient with Long COVID or you are a representing a loved one/family member who has Long COVID and you are interested in providing comments as part of a panel discussion, please indicate so during the registration process. 

All of the demographic questions are voluntary. Having a sense of attendee representation helps us with meeting planning.

For more information, please visit the FDA meeting website: https://www.fda.gov/drugs/news-events-human-drugs/public-meeting-patient-focused-drug-development-long-covid-04252023

PRIVACY NOTICE

The FDA’s collection of information in support of this public meeting is conducted in accordance with the Federal Food, Drug, and Cosmetic Act. FDA is using a third-party service and website, SurveyMonkey, to assist with event registration and collection of information from participants.

SurveyMonkey is not a government website or application. HHS and FDA privacy policies do not apply to SurveyMonkey. By using SurveyMonkey to communicate with FDA, the information you submit may be accessible to nongovernment third parties. Unless required by law, FDA will not share this information. Furnishing requested information is voluntary.

You can alternatively submit information by emailing PatientFocused@fda.hhs.gov. When submitting information by website or email, please take care not to submit unnecessary sensitive information such as Social Security number, medical records numbers, and other personal identifiers.

Additional detail regarding FDA's use of information is available online:
FDA privacy/website policies:  www.fda.gov/RegulatoryInformation/FOI/PrivacyAct/default.htm
FDA Privacy Act page: www.fda.gov/AboutFDA/AboutThisWebsite/WebsitePolicies/default.htm

Question Title

* 1. First Name

Question Title

* 2. Last Name

Question Title

* 3. Email Address

Question Title

* 4. Ethnicity (check the single best answer)

Question Title

* 5. Race (check all that apply)

Question Title

* 6. Gender

Question Title

* 7. Preferred language for meeting communications

Question Title

* 8. In what capacity will you participate in this virtual meeting?

( Privacy & Cookie Notice

T